Revance Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
© -
Good morning, everyone. I'm happy to introduce our next guest from Revance Therapeutics. Please welcome CFO, Toby Schilke.
Thanks, Matt, and thanks, Crédit Suisse, for hosting us today. It's my privilege to give you an overview of Revance Therapeutics. Again, my name is Toby Schilke. I'm the CFO of Revance Therapeutics.
This presentation contains forward-looking statements. I encourage you to read them on our website in detail and also the risk factors on Form 10-K and 10-Q of our recent SEC filings.
It's an exciting time to be at Revance. We're at the cusp of considerable amount of value-creation activities, and we've most recently announced the new CEO, Mark Foley from ZELTIQ Aesthetics. So very exciting time to be commercializing DAXI, a differentiated, longer-lasting neuromodulator in aesthetics that we hope to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |